How a Weight Loss Wonder Drug Could Fatten Your Portfolio
1 Weight Loss Drug Celebs & Investors Love
Its annual market is expected to balloon more than 16X by 2030…
I’m talking about GLP-1 agonists like Ozempic and Wegovy, revolutionary weight loss drugs that have swept America by storm. These treatments are changing more than waistlines; they're shaking up entire sectors, impacting everything from junk food giants to healthcare providers.
Goldman Sachs estimates this market will explode from $6 billion annually to $100 billion… in just 6 short years.
We foresaw this trend, recommending Novo Nordisk back in 2015, while Ozempic was still in clinical trials, leading to a 424% gain for our members. Now, we've uncovered more companies poised for significant growth amidst the GLP-1 drug wave.
Our exclusive report details these potential powerhouses... like another pharmaceutical company with a GLP-1 drug in clinical trials — a drug that is already showing longer–lasting effects than competitors on the market… with only a single dose per month.
Enter your email to learn how to become a member for 50% off* and get the full report.
Returns are updated during market hours.
*$99/year is an introductory offer for new members only. 50% discount based on current list price of Stock Advisor of $199/year. Membership will renew annually at the then-current list price.
The Motley Fool has a disclosure policy.
The Motley Fool respects your privacy and strives to be transparent about our data collection practices. We use your information to customize the site for you, to contact you about your membership, provide you with promotional information, and in aggregate to help us better understand how the service is used.
Past performance is not a predictor of future results. Individual investment results may vary. All investing involves risk of loss.